HC Wainwright Reaffirms Buy Rating for Gossamer Bio (NASDAQ:GOSS)

Gossamer Bio (NASDAQ:GOSS)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $10.00 price objective on the stock. HC Wainwright also issued estimates for Gossamer Bio’s FY2028 earnings at $0.24 EPS and FY2029 earnings at $0.55 EPS.

Separately, Wedbush reaffirmed an “outperform” rating and issued a $4.00 price objective on shares of Gossamer Bio in a report on Friday, March 14th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $9.20.

Gossamer Bio Trading Down 4.2 %

Shares of Gossamer Bio stock opened at $1.36 on Tuesday. The company has a debt-to-equity ratio of 3.64, a current ratio of 6.74 and a quick ratio of 6.74. The firm has a fifty day moving average price of $1.15 and a 200 day moving average price of $0.98. Gossamer Bio has a 1 year low of $0.50 and a 1 year high of $1.55. The stock has a market cap of $308.18 million, a PE ratio of -4.25 and a beta of 1.86.

Gossamer Bio (NASDAQ:GOSS) last issued its earnings results on Tuesday, March 18th. The company reported ($0.15) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.15). The business had revenue of $9.38 million for the quarter, compared to analysts’ expectations of $7.02 million. Equities research analysts predict that Gossamer Bio will post -0.28 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Graham Capital Management L.P. purchased a new position in Gossamer Bio in the fourth quarter valued at $32,000. US Bancorp DE acquired a new stake in shares of Gossamer Bio in the third quarter valued at about $39,000. Fullcircle Wealth LLC acquired a new stake in shares of Gossamer Bio in the fourth quarter valued at about $43,000. GSA Capital Partners LLP acquired a new stake in shares of Gossamer Bio in the third quarter valued at about $67,000. Finally, Velan Capital Investment Management LP acquired a new stake in shares of Gossamer Bio in the fourth quarter valued at about $68,000. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.